Intellia Therapeutics Inc.

In News

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) - Intellia Therapeutics

Intellia Therapeutics - Sep 08, 2026

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - stocktwits.com

stocktwits.com - Sep 11, 2026

Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? - Yahoo Finance

Yahoo Finance - Sep 10, 2026

FDA grants lonvo-z priority review - CRISPR Medicine News

CRISPR Medicine News - Sep 08, 2026

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million - Intellia Therapeutics

Intellia Therapeutics - Sep 04, 2026

If approved, a one-time treatment could be the world's first in-body gene-editing therapy for hereditary angioedema. - Stock Titan

Stock Titan - Sep 08, 2026

Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date - AllSci

AllSci - Sep 08, 2026

FDA to Decide on First In Vivo Gene Editor Next Year - GenomeWeb

GenomeWeb - Sep 09, 2026

NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - stocktwits.com

stocktwits.com - Sep 12, 2026

Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z - Yahoo Finance

Yahoo Finance - Sep 08, 2026

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference - Intellia Therapeutics

Intellia Therapeutics - Sep 04, 2026

Why Is NTLA Stock Jumping 5% Premarket Today? - stocktwits.com

stocktwits.com - Sep 12, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment